title: Predictive value of host-specific donor helper T-cell precursor frequency for acute graft-versus-host disease and relapse in HLA-identical siblings receiving allogeneic bone marrow transplantation for hematological malignancies.
abstract: BACKGROUND
  Acute graft-versus-host disease (aGVHD) is still one of the main causes of morbidity and mortality after allogeneic bone marrow transplantation. Attempts to avoid GVHD are associated with an increased risk of relapse, probably because the graft-versus-leukemia effect is also abrogated. It was recently suggested that a high frequency of host-specific donor helper T cell precursors (HTLp) might be predictive of significant aGVHD (grade > or = II).
  
  
  METHODS
  We retrospectively studied the frequency of HTLp by means of simplified limiting-dilution analysis to determine its predictive value for aGVHD and relapse. Pre-bone marrow transplantation, host-specific donor HLTp frequencies were analyzed in 32 patients who had received marrow from HLA-identical siblings for hematological malignancies, in terms of aGVHD and relapse.
  
  
  RESULTS
  HTLp frequencies were significantly higher in patients who had aGVHD > or = grade II (n=14) than in those without aGVHD (n=18) (P=0.007). Patients who relapsed (n=13) had significantly lower HTLp frequencies than those who did not relapse (n=19) (P<0.0001). The probabilities of relapse (Kaplan-Meier method) when the HTLp frequency was higher and lower than 1/200,000 were 0% and 88%, respectively (P<0.0001).
  
  
  CONCLUSIONS
  The definition of HTLp cut-off values predictive of aGVHD and relapse should contribute to donor selection and could open the way to protocols adapting immunomodulation to the likely risk of aGVHD and relapse.
authors.affiliation: Unité de Greffe de Moelle et Centre de Transfusion Sanguine, Hôpital Henri Mondor, Créteil, Val-de-Marne, France.
authors.forename: S
authors.initials: S
authors.lastname: Lachance
authors.forename: S
authors.initials: S
authors.lastname: Le Gouvello
authors.forename: F
authors.initials: F
authors.lastname: Roudot
authors.forename: M
authors.initials: M
authors.lastname: Kuentz
authors.forename: F
authors.initials: F
authors.lastname: Bernaudin
authors.forename: F
authors.initials: F
authors.lastname: Beaujean
authors.forename: P
authors.initials: P
authors.lastname: Bierling
authors.forename: C
authors.initials: C
authors.lastname: Cordonnier
authors.forename: J P
authors.initials: JP
authors.lastname: Farcet
authors.forename: J P
authors.initials: JP
authors.lastname: Vernant
mesh_terms: D000293:Adolescent; D016026:Bone Marrow Transplantation / Q000276:immunology*; D002648:Child; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D006680:HLA Antigens / Q000097:blood*; D019337:Hematologic Neoplasms / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D013234:Stem Cells / Q000166:cytology*; D006377:T-Lymphocytes, Helper-Inducer / Q000166:cytology*; D019172:Transplantation Conditioning
chemical_list: D006680:HLA Antigens